Table 2.
Systemic blood pressure and heart rate at time of Nimodipine administration (t0), Nimodipine associated hemodynamic changes, and clinical assessment.
| Day 1 | Day 3 | Day 5 | Day preceding DCI | p-value | p-value adjusted (sex, age) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-DCI | DCI | Non-DCI | DCI | Non-DCI | DCI | Non-DCI | DCI | |||
| SBP (mmHg) | 137.3 ± 12.1 | 136.3 ± 18.7 | 149.9 ± 21 | 150.4 ± 21.8 | 150.7 ± 24.7 | 163.1 ± 21.6 | 149.8 ± 23.1 | 163.4 ± 20.7 | 0.092 | 0.011* |
| MAP (mmHg) | 91.3 ± 7.1 | 90.9 ± 11.3 | 100.8 ± 15.4 | 97.7 ± 13.5 | 100.2 ± 12.9 | 107.7 ± 14.9 | 101.6 ± 9.7 | 108.9 ± 11.6 | 0.027* | 0.023* |
| DBP (mmHg) | 65.2 ± 6.1 | 65 ± 7.6 | 73.5 ± 12.8 | 69.4 ± 10.1 | 73.3 ± 10.8 | 78 ± 11.5 | 74.3 ± 7.1 | 78.7 ± 8.7 | 0.049* | 0.061 |
| HR (bpm) | 71.8 ± 11.1 | 67.9 ± 10.3 | 73.7 ± 11.5 | 66.7 ± 11.2 | 73.9 ± 14 | 71.3 ± 10.6 | 77.1 ± 12.4 | 76.7 ± 12 | 0.374 | 0.636 |
| SBP dip (mmHg) | −12.4 ± 4.6 | −11.4 ± 5.3 | −13.1 ± 4.8 | −15.4 ± 4.4 | −12.6 ± 5.6 | −19.2 ± 7.4 | −14.1 ± 7.4 | −22.3 ± 7.1 | 0.037* | <0.001* |
| MAP dip (mmHg) | −8 ± 3 | −7.3 ± 3.5 | −9.5 ± 4.3 | −8.9 ± 3.4 | −10.1 ± 6.8 | −10 ± 4.4 | −9.6 ± 3.3 | −12.6 ± 4.3 | 0.169 | 0.129 |
| DBP dip (mmHg) | −5.6 ± 2.5 | −5.4 ± 3 | −7.6 ± 3.4 | −6 ± 3.1 | −8 ± 8.1 | −6 ± 5.6 | −7.8 ± 3.7 | −9.3 ± 2.4 | 0.427 | 0.946 |
| HR dip (bpm) | 1 ± 3 | −1.3 ± 5.2 | 1.2 ± 4.7 | 1.8 ± 4.6 | 1.1 ± 4.3 | 1.8 ± 4.1 | 0.4 ± 4.0 | 0.1 ± 5.6 | 0.970 | 0.936 |
| GCS | 12.2 ± 2.4 | 11.9 ± 2.5 | 13.1 ± 1.4 | 12.9 ± 1.8 | 13.5 ± 1.3 | 13.9 ± 1.1 | 13.9 ± 1 | 13.3 ± 1.8 | 0.162 | 0.950 |
| RASS | −0.6 ± 1 | −1.1 ± 1.3 | −0.3 ± 0.8 | −0.8 ± 0.9 | −0.5 ± 1 | −0.2 ± 0.8 | 0.1 ± 0.8 | −0.3 ± 0.9 | 0.161 | 0.590 |
Values represent means ± Standard deviation.
*
p ≤ 0.05 DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.